Skip to main content
. 2021 May 21;9(1):498–526. doi: 10.1080/21642850.2021.1929236

Table 5.

Efficacy of treatment at 1-month follow-up using sensitivity analysis.

  MyCB (n = 8) MyCB + M (n = 4) EW (n = 11) Main Effect Time Main Effect Group Group x Time Interaction
  M (SD) M (SD) M p/95% CI p/95% CIa F p/95% CIa
Body Image Distress              
Baseline 10.99 (7.44) 11.42 (6.19) 14.56 (7.35) <.01*
(1.97, 3.97)
.74
(−7.30, 8.44)
(−8.26, 6.91)
1.69 .21
(−1.11, 5.84)
(−3.39, 3.89)
1-month F/U 9.75 (7.44) 10.42 (6.19) 10.99 (7.35)
Body Appreciation              
Baseline 3.48 (.64) 3.98 (.53) 3.37 (.63) .13
(−0.42, 0.26)
.20
(−1.21, 0.151)
(−1.11, 0.21)
.08 .92
(−0.48, 0.32)
(−0.47, 0.37)
1-month F/U 3.61 (.64) 4.06 (.53) 3.53 (.63)
Trait Self-Compassion              
Baseline 39.991 (10.89) 38.642 (9.06) 39.751,2 (3.25) <.05*
(−13.13, −1.87)
.83
(−16.13, 6.99)
(−18.81, 3.52)
3.65 .04*
(0.90, 12.26)
(2.10, 15.90)
1-month F/U 38.48 (10.89) 46.14 (9.06) 41.57 (3.25)
Depression              
Baseline 2.26 (4.13) 3.99 (3.42) 2.80 (4.09) .76
(−0.99, 2.99)
.88
(−4.48, 4.27)
(−4.46, 3.99)
.82 .45
(−3.41, 1.23)
(−3.93, 0.93)
1-month F/U 2.76 (4.13) 2.99 (3.42) 2.89 (4.09)
Anxiety              
Baseline 1.44 1 (3.20) 6.242 (2.66) 1.751 (3.32) .02*
(1.71, 5.29)
.17
(−4.37, 2.40)
(−6.32, 1.93)
8.12 <.01*
(−5.59, −1.41)
(−6.32, −1.93)
1-month F/U 2.07 (3.20) 2.74 (2.66) 1.75 (3.32)
Stress              
Baseline 5.16 (4.44) 7.04 (3.73) 5.67 (4.39) .36
(−0.87, 5.37)
.92
(−3.64, 5.78)
(−4.08, 5.07)
1.05 .37
(−6.08, 1.21)
(−6.20, 1.45)
1-month F/U 5.28 (4.44) 4.77 (3.73) 5.86 (4.39)

Note: Adjusted means and standard deviations reported. Controlling for age, lymphoedema status and total complications reported at baseline.

aConfidence intervals are reported for contrasts: EW vs. MyCB + M, MyCB vs. MyCB + M

1,2

Denotes contrasts conducted following significant group x time interaction: same number indicates no significant difference, and different numbers indicate significant difference. * p<.05.